Skip to main content

Table 2 Comparison of demographics and WMHs between the improved and non-improved groups

From: Association of white matter hyperintensities with migraine features and prognosis

 

Improved

group (n = 15)

Non-improved

group (n = 18)

P-value

Age (year, mean ± SD)

29.5 ± 9.8

34.7 ± 11.0

0.166

Gender

  

1.000

 Female, n (%)

13 (86.7%)

16 (88.9%)

 

 Male, n (%)

2 (13.3%)

2 (11.1%)

 

BMI (kg/m2, mean ± SD)

19.9 ± 2.3

21.1 ± 2.9

0.203

Headache characteristics

 Aura, n (%)

9 (60.0%)

2 (11.1%)

0.008*

 Disease duration (month, quartile)

72 (24, 144)

150 (48, 279)

0.096

 Attack frequency (day/month, quartile)

4.0 (2.0, 7.0)

2.0 (2.0, 5.5)

0.555

 Attack duration (hour, quartile)

4.5 (2.0, 10.0)

11.0 (3.4, 24.0)

0.204

 Visual analogue scale, mean ± SD

7.0 (6.0, 7.9)

8.0 (7.0, 9.3)

0.051

Medications

 Prophylactic medications#, n (%)

5 (33.3%)

4 (22.2%)

0.697

 Medication overuse#, n (%)

1 (6.7%)

2 (11.1%)

1.000

  1. *A significance level, P < 0.05; #The number of patients who took regular prophylactic medications for more than 3 months or had medication overuse during the follow-up period; SD standard deviation, BMI body mass index